HR Execs on the Move

Nexus

www.nexustreatment.org

 
Nexus operates 6 residential treatment sites with programming accredited by COA or TJC, and year-round, on-site schools, as well as inpatient psychiatric care programs, foster care and adoption, in-home counseling services, and ongoing support. Our programs offer a continuum of services to provide boys and girls a safe place to face their past and begin their future. We operate sites and services in Minnesota, Illinois, Maryland, North Dakota, and Idaho, each offering specialized treatment options for your child`s or adolescent`s needs. Mille Lacs Academy Gerard Academy Nexus Glen Lake Indian Oaks Academy Onarga Academy Woodbourne Center Kindred Family Focus PATH ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Monument

Monument is an online treatment platform for those looking to change their relationship with alcohol.

Field Crest Care Ctr

Field Crest Care Ctr is a Hayfield, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Brevium

Brevium is a South Jordan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Medical Home Health Services and Home Resources

American Medical Home Health Services & Home Resources is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.